Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection

Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection

It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study.

Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.

Patients will be randomized to one of the treatment groups:

• SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50)
• PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Inclusion Criteria:

• Age 18 years or more.
• Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.
• Signature of Patient's Consent or Verbal Consent of Legal Representative

Exclusion Criteria:

• Intracranial hypertension
• Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients
• Current volume < 250ml
• History of malignant hyperthermia
• Liver failure
• Neutropenia (<0.5x109)
• Pregnant or lactating women
• Have received chemotherapy in the last month since their inclusion in the study